Compare Micron Technology, Inc. (MU) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Novartis AG — how do they compare? Micron Technology, Inc. trades at $879.77 (market cap $972.41B), while Novartis AG trades at $154.71 (market cap $298.18B). The key difference: Micron Technology, Inc. is far larger — about 3.3× Novartis AG's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| MU | NVS | |
|---|---|---|
Market Cap | $972.41B | $298.18B |
Sector | Technology | Health |
52-Week High | $1.21K | $168.62 |
52-Week Low | $115.79 | $119.31 |
Enterprise Value | $952.76B | $339.50B |
Dividend Yield | 0.06% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $877.57, down 0.44% on the day, with technical indicators showing a neutral overall signal and bullish moving averages. The company reported strong earnings beats in recent quarters, including Q1 2026 EPS of $25.11 versus $20.98 expected, driven by robust AI memory demand. Revenue surged to $37.38 billion in 2025, with net income margin at 55.91%. Analyst consensus is overwhelmingly bullish with an 81.43% buy rating and a $1,540 price target.
Outlook remains positive due to structural demand for high-bandwidth memory in AI, but risks include cyclical pricing pressures and competitive capacity expansions. The stock offers growth potential amid tight supply conditions, though volatility from valuation concerns and macroeconomic factors persists. Key support sits at $848 with resistance at $906.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
